Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Elliptic Laboratories ASA is a Norwegian artificial intelligence software company specializing in AI Virtual Smart Sensors for smartphones, laptops, Internet of Things devices, and automotive markets. Founded in 2006 as a spin-off from the University of Oslo, the company develops a scalable AI platform that leverages ultrasound, sensor-fusion algorithms, and machine learning to create software-only sensors, replacing traditional hardware for enhanced sustainability and eco-friendliness. Key offerings include the AI Virtual Human Presence Sensor for security and intuitive interactions, AI Virtual Proximity Sensor enabling full-screen designs, AI Virtual Gesture Sensor for touchless controls, and wellness sensors like AI Virtual Breathing and Heart Sensors to monitor vital signs. With headquarters in Oslo and offices in the United States, China, South Korea, Taiwan, and Japan, Elliptic Laboratories ASA powers nearly 1 billion devices worldwide through partnerships with major manufacturers such as Lenovo, AMD, Intel, VIVO, and Huawei, driving contextual intelligence that makes devices smarter and more human-centric. Employing 88 professionals, it operates in the technology sector's software infrastructure space, fostering innovation in user experience and environmental consciousness.
NOK 0.22
NOK 0.00 (-0.23%)
EOD Jul 1, 2026
The business is unprofitable at the operating level (-46.63% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 23.2% YoY. Margins deteriorated 46.4pp alongside, both lines moving the wrong way.
ROIC dropped from -0.05% to -13.68%, capital efficiency is deteriorating. Negative free cash flow of -NOK 23M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
NOK 126M
▼ -23.2% YoY
Net Income (TTM)
-NOK 122M
▼ -1661.9% YoY
Op. Margin
-18.61%
▼ -46.4pp YoY
ROIC
-13.68%
▼ -13.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-NOK 51M
▲ +43.8% YoY
Op. Cash Flow (TTM)
-NOK 43M
▲ +49.7% YoY
Net Debt
-NOK 25M
Net Cash Position
Cash & Equiv.
NOK 38M
3Y CAGR: +24.8%
Continue Research
Elliptic Laboratories ASA (ELABS.XOSL)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Elliptic Laboratories ASA scores 43/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Elliptic Laboratories ASA scores 43 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a -18.6% operating margin and a -13.7% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh ELABS.XOSL's valuation and scores 43/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.